Drugs / CSJ117
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT03138811 | Dec 2017 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04882124 | Sep 2021 → Sep 2022 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04946318 | Sep 2021 → Sep 2022 | asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04410523 | Sep 2020 → Jul 2022 | asthma | Novartis Pharmaceuticals | Terminated | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSJ117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882124 ↗ |
| Known as | ecleralimab | “Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen.” PMID 36822634 ↗ Mar 2023 |
| Action | Inhibit | “neutralising antibody fragment against human TSLP” PMID 36822634 ↗ Mar 2023 |
| Modality | Protein / enzyme biologic | “a potent inhaled neutralising antibody fragment against human TSLP” PMID 36822634 ↗ Mar 2023 |
| Route | Inhaled | “4 mg once-daily inhaled ecleralimab” PMID 36822634 ↗ Mar 2023 |
| Target | TSLP | “against human TSLP” PMID 36822634 ↗ Mar 2023 |